Delphi Diagnostics has appointed Eric Lindquist as its new Chief Financial Officer, effective April 1, 2026, marking a significant step in its growth strategy.
With extensive experience in the oncology and diagnostics sectors, Lindquist aims to enhance the financial strategy of Delphi as it focuses on advancing its Endocrine Activity Index® (EAI™) test. This test is designed to aid in treatment decision-making for breast cancer, particularly for patients with stage II-III, HR+ HER2- breast cancer. Lindquist's previous roles include CEO of InnoSIGN and Chief Business and Commercial Officer at Celcuity, where he was pivotal in advancing breast cancer therapies.
Delphi Diagnostics’ CEO, Winz Casagrande, emphasized Lindquist's expertise in oncology and strategic finance as crucial for the company’s next growth phase. Lindquist expressed enthusiasm about the potential of the EAI test to clarify complex clinical decisions, underscoring his commitment to driving long-term value for the company.
This appointment comes at a time when Delphi seeks to expand access to innovative breast cancer diagnostics, positioning itself as a leader in personalized treatment solutions. With Lindquist's leadership, the company looks to leverage its unique biology-driven approach to enhance patient outcomes.